Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 19;15:54. doi: 10.1186/s12964-017-0210-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — Role of IL6R in tumour growth in vivo. a IHC staining for IL6R from intracranial tumours demonstrating IL6R silencing in M1-IL6R-shRNA1 and M1-IL6R-shRNA2 injected mice. Scale bar = 25 μm. Kaplan–Meier survival curves show the survival differences of mice injected with M1-control-shRNA, M1-IL6R-shRNA1 and M1-IL6R-shRNA2 cells, respectively. b IL6R knockdown significantly inhibited intracranial tumour growth. c IL6R silencing significantly inhibited subcutaneous tumour growth. d IHC staining for IL6R from intracranial tumours demonstrating IL6R overexpression in N2-IL6R-OE injected mice. Scale bar = 25 μm. Kaplan–Meier survival curves show the survival differences of mice injected with N2-EV-control and N2-IL6R-OE cells, respectively. e IL6R overexpression promoted intracranial tumour growth. f IL6R overexpression significantly increased subcutaneous tumour growth. *P < 0.05 and **P < 0.01